PAVmed Community

NasdaqCM:PAVM Community

1 Narratives written by author
0 Comments on narratives written by author
1 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

EsoGuard, Lucid, And Veris Will Shape Industry Future Amid Risks

Key Takeaways Expected growth from EsoGuard and Lucid Diagnostics' program could significantly boost revenues and cash flow management due to insurance coverage and strong execution. Strategic partnerships and advancements with Veris Health, including potential FDA clearance, are likely to enhance commercial potential and market differentiation.

US$9.00

FV

92.7% undervalued

269.43%

Revenue growth p.a.

0

0

1

20 days ago